909
Views
6
CrossRef citations to date
0
Altmetric
Editorials

Mechanism of action of resveratrol in lipid metabolism and atherosclerosis

Pages 527-531 | Published online: 18 Jan 2017

  • Gugliucci A, Menini T: Three different pathways for human LDL oxidation are inhibited in vitro by water extracts of the medicinal herb Achyrocline satureoides. Life Sci. 71, 693–705 (2002).
  • Kaliora AC, Dedoussis GV, Schmidt H: Dietary antioxidants in preventing atherogenesis. Atherosclerosis 187, 1–17 (2006).
  • Xu BJ, Yuan SH, Chang SK: Comparative studies on the antioxidant activities of nine common food legumes against copper­ induced human low­density lipoprotein oxidation in vitro. J. Food Sci. 72, S522–S527 (2007).
  • Tunstall­Pedoe H, Kuulasmaa K, Mahonen M et al.: Contribution of trends in survival and coronary­event rates to changes in coronary heart disease mortality: 10­year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353, 1547–1557 (1999).
  • Fremont L, Belguendouz L, Delpal S: Antioxidant activity of resveratrol and alcohol­free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 64, 2511–2521 (1999).
  • Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM: Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 9, 77–79 (2002).
  • Araim O, Ballantyne J, Waterhouse AL, Sumpio BE: Inhibition of vascular smooth muscle cell proliferation with red wine and red wine polyphenols. J. Vasc. Surg. 35, 1226–1232 (2002).
  • Tsai SH, Lin­Shiau SY, Lin JK: Suppression of nitric oxide synthase and the down­ regulation of the activation of NFkB in macrophages by resveratrol. Br. J. Pharmacol. 126, 673–680 (1999).
  • de Lorgeril M, Salen P: Diet as preventive medicine in cardiology. Curr. Opin. Cardiol. 15, 364–370 (2000).
  • Haberland ME, Fong D, Cheng L: Malondialdehyde­altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241, 215–218 (1988).
  • Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A: Susceptibility to low­density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339, 1183–1186 (1992).
  • Heinecke JW: Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141, 1–15 (1998).
  • Berrougui H, Grenier G, Loued S, Drouin G, Khalil A: A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis DOI: 10.1016/j.atherosclerosis.2009.05.017 (2009) (Epub ahead of print).
  • Reports the mechanism underlying the antiatherogenic properties of resveratrol by investigating its antioxidant effect on lipoprotein particles, its effect on cholesterol homeostasis and the relationship between prevention of lipoproteins and cells from oxidation by resveratrol, as well as its impact on the cholesterol efflux process, especially by upregulating ATP-binding cassette transporter (ABC) A1 expression.
  • Belguendouz L, Fremont L, Gozzelino MT: Interaction of transresveratrol with plasma lipoproteins. Biochem. Pharmacol. 55, 811–816 (1998).
  • Belguendouz L, Fremont L, Linard A: Resveratrol inhibits metal ion­dependent and independent peroxidation of porcine low­density lipoproteins. Biochem. Pharmacol. 53, 1347–1355 (1997).
  • Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP: Effects of resveratrol on the rat brain respiratory chain. Drugs Exp. Clin. Res. 25, 87–97 (1999).
  • Girona J, LaVille AE, Sola R, Motta C, Masana L: HDL derived from the different phases of conjugated diene formation reduces membrane fluidity and contributes to a decrease in free cholesterol efflux from human THP­1 macrophages. Biochim. Biophys. Acta 1633, 143–148 (2003).
  • Marcil V, Delvin E, Sane AT, Tremblay A, Levy E: Oxidative stress influences cholesterol efflux in THP­1 macrophages: role of ATP­binding cassette A1 and nuclear factors. Cardiovasc. Res. 72, 473–482 (2006).
  • Contributes to determine the role of oxidative stress-mediated lipid peroxidation in cholesterol influx and efflux in macrophages, by assessing the gene and protein expression of PPAR, liver X receptors, scavenger receptor class B type I, ABCA1 and CD36.
  • Fredenrich A, Bayer P: Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab. 29, 201–205 (2003).
  • Berrougui H, Isabelle M, Cloutier M, Grenier G, Khalil A: Age­related impairment of HDL­mediated cholesterol efflux. J. Lipid Res. 48, 328–336 (2007).
  • Jaouad L, Milochevitch C, Khalil A: PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic. Res. 37, 77–83 (2003).
  • Pirillo A, Uboldi P, Kuhn, H, Catapano AL: 15­lipoxygenase­mediated modification of high­density lipoproteins impairs SR­BI­ and ABCA1­dependent cholesterol efflux from macrophages. Biochim. Biophys. Acta 1761, 292–300 (2006).
  • Oram JF, Heinecke JW: ATP­binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85, 1343–1372 (2005).
  • Wang N, Silver DL, Costet P, Tall AR: Specific binding of ApoA­I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 275, 33053–33058 (2000).
  • Vaughan AM, Oram JF: ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J. Lipid Res. 44, 1373–1380 (2003).
  • Sevov M, Elfineh L, Cavelier LB: Resveratrol regulates the expression of LXR­a in human macrophages. Biochem. Biophys. Res. Commun. 348, 1047–1054 (2006).
  • Demonstrates that resveratrol modulates expression of the genes involved in lipid uptake and efflux, suggesting that polyphenols can potentially limit cholesterol accumulation in human macrophages.
  • Tsang C, Higgins S, Duthie GG et al.: The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers. Br. J. Nutr. 93, 233–240 (2005).
  • Shih DM, Gu L, Xia YR et al.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–287 (1998).
  • Demonstrates that resveratrol induces the expression of PON1 in human hepatic cells.
  • Ahn J, Cho I, Kim S, Kwon D, Ha T: Dietary resveratrol alters lipid metabolism­ related gene expression of mice on an atherogenic diet. J. Hepatol. 49, 1019–1028 (2008).
  • Khalil A, Jay­Gerin JP, Fulop T Jr: Age­ related increased susceptibility of high­density lipoproteins (HDL) to in vitro oxidation induced by g­radiolysis of water. FEBS Lett. 435, 153–158 (1998).
  • Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY: Resveratrol attenuates the expression of HMG­CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 367, 190–194 (2008).
  • Zern TL, Wood RJ, Greene C et al.: Grape polyphenols exert a cardioprotective effect in pre­ and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J. Nutr. 135, 1911–1917 (2005).
  • Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
  • Joy T, Hegele RA: The end of the road for CETP inhibitors after torcetrapib? Curr. Opin. Cardiol. 24, 364–371 (2009).
  • Zang M, Xu S, Maitland­Toolan KA et al.: Polyphenols stimulate AMP­activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor­ deficient mice. Diabetes 55, 2180–2191 (2006).
  • Baur JA, Pearson KJ, Price NL et al.: Resveratrol improves health and survival of mice on a high­calorie diet. Nature 444, 337–342 (2006).
  • Findings in this study demonstrate that resveratrol shifts the physiology of mice consuming excess calories towards that of mice on a standard diet, modulates known longevity pathways and improves health.
  • Hou X, Xu S, Maitland­Toolan KA et al.: SIRT1 regulates hepatocyte lipid metabolism through activating AMP­activated protein kinase. J. Biol. Chem. 283, 20015–20026 (2008).
  • Howitz KT, Bitterman KJ, Cohen HY et al.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196 (2003).
  • Milne JC, Lambert PD, Schenk S et al.: Small molecule activators of SIRT1 as therapeutics for the treatment of Type 2 diabetes. Nature 450, 712–716 (2007).
  • Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377–1382 (2004).
  • Potter GA, Patterson LH, Wanogho E et al.: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 86, 774–778 (2002).
  • Goldberg DM, Yan J, Soleas GJ: Absorption of three wine­related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36, 79–87 (2003).
  • Gescher AJ, Steward WP: Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 12, 953–957 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.